CN1084205C - Medicine for treating disease of upper respiratory tract and its preparation - Google Patents
Medicine for treating disease of upper respiratory tract and its preparation Download PDFInfo
- Publication number
- CN1084205C CN1084205C CN99114946A CN99114946A CN1084205C CN 1084205 C CN1084205 C CN 1084205C CN 99114946 A CN99114946 A CN 99114946A CN 99114946 A CN99114946 A CN 99114946A CN 1084205 C CN1084205 C CN 1084205C
- Authority
- CN
- China
- Prior art keywords
- medicine
- radix
- kilograms
- upper respiratory
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to medicine for treating upper respiratory diseases and a preparation method thereof. The medicine is prepared from the following raw materials according to certain processes: 20 to 30 wt% of brook anemone, 15 to 25 wt% of figwort root, 15 to 25 wt% of blackberrykiky rhizome, 15 to 25 wt% of great burdock achene, 15 to 25 wt% of stickyhair pearleverlasting herb, 10 to 20 wt% of platycodon root, 10 to 20 wt% of tangerine peel and 10 to 20% of licorice root. The present invention is characterized in that the medicine is prepared on the basis of finding and finishing folk ethnic medicine. The medicine for treating acute and chronic pharyngitis, tonsillitis, bronchitis and other upper respiratory diseases has obvious functions of diminishing inflammation, relieving cough, reducing phlegm and resisting bacteria, and has favorable therapeutical effect of treating symptoms such as swelling and pain in throat, cough, excessive phlegm, fever, bitter taste of mouths, rhinobyon, etc. caused by pityriasis rosea, and sthenic fever of the lung and the stomach.
Description
The present invention relates to a kind of medicine for the treatment of upper respiratory disease, specifically is Chinese patent medicine of feedstock production and preparation method thereof with Chinese medicine.
Though at present the medicine for the treatment upper respiratory disease is many, effect is not remarkable, and what have only is adapted to wind-heat syndrome, and what have only is applicable to lung excess of the stomach heat syndrome.Two kinds of all medicative medicines of disease type still are not reported.Western medical treatment main with antibiotic be main, very fast to the controlling symptoms effect, but its side effect is bigger, can not life-time service, and the treatment back easily.
The object of the present invention is to provide a kind of common acute/chronic pharyngitis for the treatment of, tonsillitis, the bronchitis curative effect is better than similar Chinese patent medicine, craft science, the medicine of stay-in-grade upper respiratory disease, and its preparation method.
Solution of the present invention is to use the advantageous resources of medicinal plant in Yunnan, and various nationalities' ethnic drug with local characteristic of excavating and create in combating the disease for a long time.The present invention excavates and arrangement by the collection to ethnic drug folk prescription, proved recipe, and it has been done a large amount of research, screening, analysis of experiments, and work such as contrast experiment draw scientific and reasonable prescription of the present invention and advanced technology.The present invention is principal agent with the Radix Anemones Rivularis, heat-clearing and toxic substances removing, and the sharp larynx of dispelling wind, the moistening and cleaning throat cough-relieving, Fructus Arctii reducing heat and dispersing lung-QI sore-throat relieving share with Radix Anemones Rivularis and to help its heat-clearing and toxic substances removing, pharynx-clearing throat-benefiting; The Herba Clematidis Meyenianae diffusing wind that can induce sweat, assistant principal agent heat clearing away and do not make invasion of pathogenic factor from the exterior into the interior, the face of dispersing does not help heat; Radix Platycodonis can be opened the lung key, goes into lung meridian, and it is up to draw all medicines, the heat-clearing and toxic substances removing of building together, relieving sore throat and diminishing swelling, preventing phlegm from forming and stopping coughing, the merit that a surname's numbness is had one's ideas straightened out.
The present invention is made by following prescription: (consumption is a weight portion)
Radix Anemones Rivularis 20-30 Radix Scrophulariae 15-25 Rhizoma Belamcandae 15-25
Fructus Arctii 15-25 Herba Clematidis Meyenianae 15-25 Radix Platycodonis 10-20
Pericarpium Citri Reticulatae 10-20 Radix Glycyrrhizae 10-20
Optimum weight of the present invention (part) proportioning is:
Radix Anemones Rivularis 25 Radix Scrophulariaes 20 Rhizoma Belamcandae 20 Herba Clematidis Meyenianaes 20
Fructus Arctii 20 Radix Platycodoniss 15 Pericarpium Citri Reticulataes 15 Radix Glycyrrhizaes 15
The pharmaceutical dosage form of above-mentioned treatment upper respiratory disease is said dosage form on any pharmaceutics.
The pharmaceutical dosage form of treatment upper respiratory disease of the present invention is capsule or oral liquid.Its preparation method is:
Capsular producing is medical material to be cleaned add water 6-8 and doubly soak more than 1 hour, decocts three times, and boiling time is 1 hour at every turn; Merge three times decoction liquor, being concentrated into relative density is 1.24-1.28; Above-mentioned medicinal liquid is added four times of amount ethanol, make solution contain the alcohol amount and be about 72%, left standstill 36 hours; The supernatant of getting behind the precipitate with ethanol filters on 200 mesh sieves, and filtrate recycling ethanol is not to there being the alcohol flavor, and being concentrated into relative density is 1.38-1.42; Get starch and be laid in right amount in the dish, extractum is evenly distributed in the dish, carry out drying in 80 ℃ of following temperature; With the pulverizing of gained dry extract, weighing, add starch to add to required total amount by total amount, mix homogeneously is made soft material in right amount with 95% ethanol, granulates drying.
Producing of oral liquid is to be raw material for 1.5 kilograms with 2.5 kilograms of Radix Anemones Rivulariss, 2 kilograms of Radix Scrophulariaes, 2 kilograms of Rhizoma Belamcandae, 2 kilograms of Fructus Arctiis, 2 kilograms of Herba Clematidis Meyenianaes, 1.5 kilograms of Radix Platycodoniss, 1.5 kilograms of Pericarpium Citri Reticulataes, Radix Glycyrrhizae, with the Herba Clematidis Meyenianae intercept, all the other each components are ground into coarse powder, be mixed, decoct three times, each decocting time is one hour, merges three times decoction liquor, filters while hot; It is 1.20-1.25 that filtrate is concentrated into relative density, stirs 95% the ethanol that adds 1.5 times of capacity down, airtight, leave standstill about 36 hours; Get supernatant and filter, filter with 3-4 back of the heavy earnest of 85% washing with alcohol, merging filtrate is recycled to does not have the alcohol flavor, and it is an amount of to add Mel, adds to inject water to 10000 milliliter, and the adjustment pH value is 4.0-5.0, is loaded on after the check in the bottle, sterilizes, promptly.
Characteristics of the present invention are to formulate on the basis and form excavating and sorting out ethnic drug among the people.Have obvious anti-inflammatory and anti, the relieving cough and reducing sputum, antibacterial action is treatment acute/chronic pharyngitis, tonsillitis, the medicine of upper respiratory diseases such as bronchitis.Symptoms such as the laryngopharynx swelling and pain that causes for wind heat disease and lung excess of the stomach heat symptom-complex, cough, abundant expectoration, heating, bitter taste, nasal obstruction have therapeutical effect preferably.Compare with existing similar drug, have the curative effect height, applied range is through 100 many cases clinical verification total effective rates 93.6% (clinical test results sees the following form).Toxicological test proof this product safety coefficient is bigger, has no side effect.Prescription of the present invention is scientific and reasonable, technology advanced person, steady quality.
Anxious toxicity test of the present invention: select 20 of 18-22 gram mices for use, male and female half and half, after the fasting 12 hours, (dosage of (crude drug amount) is respectively irritated stomach once in the upper and lower noon with 100 gram/kilograms, 6 hours at interval, mice with Cmax and maximum volume gastric infusion after one hour, movable number of times obviously reduces, medicine progressively recovered after 4 hours, and all the other do not see the overt toxicity reaction.After the secondary administration, react as the same.Observed seven days none animal dead continuously.Put to death and dissect mice, internal organs such as the perusal heart, liver, spleen, lung, kidney also show no obvious abnormalities.This experiment repeats twice, as a result unanimity.
Following table is a pharmacodynamic experiment of the present invention
(1) drug sensitive experiment result
| Group | Dosage (/kg ± 3d) | Number of animals (only) | Ear's swelling degree (X ± SD.mg) | The P value |
| Matched group (distilled water) | 20ml | 10 | 16.7±2.3 | |
| Aspirin | 0.2g | 10 | 7.2±2.8 | ＜0.01 |
| The present invention's (capsule, oral liquid) I | 30g | 10 | 8.7±3.3 | ＜0.01 |
| The present invention's (capsule, oral liquid) II | 15g | 10 | 10.5±4.5 | ＜0.01 |
| The present invention's (capsule, oral liquid) III | 7.5g | 10 | 11.5±4.0 | ＜0.01 |
Test shows, the inhibitory action of the highly significant of the ear's inflammation due to oral medicine xylol of mice.
(3) antitussive effect
Through medicine of the present invention sulfur dioxide is caused the antitussive experiment of coughing mice, sulfur dioxide is caused the mice that coughs all significant antitussive effect, compares P＜0.05 with matched group (normal saline).
The anxious toxicity test of the animal of medicine of the present invention: select 20 of 18-22 gram mices for use, male and female half and half, after the fasting 12 hours, (dosage of (crude drug amount) is respectively irritated stomach once in the upper and lower noon with 100 gram/kilograms, 6 hours at interval, mice with Cmax and maximum volume gastric infusion after one hour, movable number of times obviously reduces, medicine progressively recovered after 4 hours, and all the other do not see the overt toxicity reaction.After the secondary administration, react as the same.Observed seven days none animal dead continuously.This experiment repeats twice, as a result unanimity.The maximum tolerated dose of oral this medicine is 200 gram/kilograms in the mice one day, and 222 times of consumption every day that is equivalent to be grown up show that this poison of drug is minimum, and safety coefficient is bigger.
Clinical experiment of the present invention:
Testing its result by medicine typing is: the effective percentage to wind-heat syndrome is 97.2%, is 100% to lung excess of the stomach heat syndrome effective percentage, evident in efficacyly is higher than same veriety.
The result shows: medicine of the present invention all is higher than similar drug to pharyngalgia, pharyngeal hyperemia, outstanding red and swollen, the heating of hanging down, the cough five kinds of cardinal symptom total effective rates of coughing up phlegm of stopping up.
Conclusion is a clinical drug determined curative effect of the present invention, takes safety, has no side effect, and is worth of widely use.
Fig. 1 is a capsule manufacture process chart of the present invention;
Fig. 2 is an oral liquid process flow chart of the present invention.
Embodiment 1:
Take by weighing raw material (kilogram) by following proportioning and produce oral liquid:
Radix Anemones Rivularis 2.5 Radix Scrophulariaes 2.0 Rhizoma Belamcandae 2.0 Fructus Arctiis 2.0
Herba Clematidis Meyenianae 2.0 Radix Platycodoniss 1.5 Pericarpium Citri Reticulataes 1.5 Radix Glycyrrhizaes 1.5
Preparation method is as follows:
(1) with the Herba Clematidis Meyenianae intercept, all the other each components are ground into coarse powder, fully are mixed;
(2) add water an amount of (surpassing medical material face 5-10cm), heating decocts three times, adds the pre-soaked medical material of water 1 hour for the first time, second and third time adds water logging and crosses the about 5cm of medical material, and each decocting time is one hour, merges three times decoction liquor, filter while hot, the medicinal residues squeezing is incorporated in the filtrate after the filtration of squeezing the juice;
(3) above-mentioned filtrate is concentrated into 10000ml (relative density is 1.20-1.25,60 ℃ heat survey), stirs 95% the ethanol (making solution content alcohol amount be about 57%) that adds 1.5 times of capacity down, airtight, leave standstill (cold preservation in case of necessity) about 36 hours.
(4) get supernatant and filter, filter with 3-4 back of 85% washing with alcohol precipitate, merging filtrate is recycled to does not have the alcohol flavor, and it is an amount of to add Mel, adds the injection water to 10000ml, and levelling pH value is 4.0-5.0, adorns after the check in the ampoule, sterilizes, promptly.
Embodiment 2:
Take by weighing raw material (kilogram) by following proportioning and produce capsule:
Radix Anemones Rivularis 625 Radix Scrophulariaes 500 Rhizoma Belamcandae 500 Fructus Arctiis 500
Herba Clematidis Meyenianae 500 Radix Platycodoniss 375 Pericarpium Citri Reticulataes 375 Radix Glycyrrhizaes 375
Preparation method is as follows:
(1) medical material is cleaned added water 6-8 and doubly soak more than 1 hour, decocts three times, each amount of water of second and third time was advisable to soak medical material surface 6-8cm, and boiling time is 1 hour at every turn.
(2) merge three decoction liquor, be concentrated into relative density and be 1.24-1.28 (30 ℃ time survey).
(3) above-mentioned gained medicinal liquid is added four times of amount ethanol, make solution contain the alcohol amount and be about 72%, left standstill 36 hours.
(4) supernatant of getting behind the precipitate with ethanol filters on 200 mesh sieves, and filtrate recycling ethanol is 1.38-1.42 (30 ℃ time survey) to not having the alcohol flavor, being concentrated into relative density.
(5) get starch and be laid in right amount in the dish, extractum is evenly distributed in the dish, carry out drying in 80 ℃ of following temperature.
(6) with the pulverizing of gained dry extract, weighing, add starch to add to required total amount by total amount, mix homogeneously is made soft material in right amount with 95% ethanol, granulate, drying after dried granule quality inspection is qualified, (is equivalent to every and contains crude drug 4.5 grams) in incapsulating, the capsule polishing, be pressed into plastic-aluminum, packing gets product.
Claims (6)
1, a kind of medicine for the treatment of upper respiratory disease is characterized in that being made by the following weight proportion raw material:
Radix Anemones Rivularis 20-30 Radix Scrophulariae 15-25 Rhizoma Belamcandae 15-25
Fructus Arctii 15-25 Herba Clematidis Meyenianae 15-25 Radix Platycodonis 10-20
Pericarpium Citri Reticulatae 10-20 Radix Glycyrrhizae 10-20
2, by the medicine of the described treatment upper respiratory disease of claim 1, wherein each raw material weight proportion be:
Radix Anemones Rivularis 25 Radix Scrophulariaes 20 Rhizoma Belamcandae 20 Herba Clematidis Meyenianaes 20
Fructus Arctii 20 Radix Platycodoniss 15 Pericarpium Citri Reticulataes 15 Radix Glycyrrhizaes 15
3, by the medicine of claim 1 or 2 described treatment upper respiratory diseases, the dosage form that it is characterized in that it is a said dosage form on any pharmaceutics.
4, by the medicine of the described treatment upper respiratory disease of claim 3, it is characterized in that said medicament is capsule or oral liquid.
5, by the preparation method of the medicine of the described treatment upper respiratory disease of claim 4, it is characterized in that capsular producing is medical material to be cleaned add water 6-8 and doubly soak more than 1 hour, decocts three times, boiling time is 1 hour at every turn; Merge three times decoction liquor, being concentrated into relative density is 1.24-1.28; Above-mentioned medicinal liquid is added four times of amount ethanol, make solution contain the alcohol amount and be about 72%, left standstill 36 hours; The supernatant of getting behind the precipitate with ethanol filters on 200 mesh sieves, and filtrate recycling ethanol is not to there being the alcohol flavor, and being concentrated into relative density is 1.38-1.42; Get starch and be laid in right amount in the dish, extractum is evenly distributed in the dish, carry out drying in 80 ℃ of following temperature; With the pulverizing of gained dry extract, weighing, add starch to add to required total amount by total amount, mix homogeneously is made soft material in right amount with 95% ethanol, granulates drying.
6, press the preparation method of the medicine of the described treatment upper respiratory disease of claim 4, it is characterized in that producing of oral liquid is is raw material for 1.5 kilograms with 2.5 kilograms of Radix Anemones Rivulariss, 2 kilograms of Radix Scrophulariaes, 2 kilograms of Rhizoma Belamcandae, 2 kilograms of Fructus Arctiis, 2 kilograms of Herba Clematidis Meyenianaes, 1.5 kilograms of Radix Platycodoniss, 1.5 kilograms of Pericarpium Citri Reticulataes, Radix Glycyrrhizae, with the Herba Clematidis Meyenianae intercept, all the other each components are ground into coarse powder, be mixed, decoct three times, each decocting time is one hour, merge three times decoction liquor, filter while hot; It is 1.20-1.25 that filtrate is concentrated into relative density, stirs 95% the ethanol that adds 1.5 times of capacity down, airtight, leave standstill about 36 hours; Get supernatant and filter, filter with 3-4 back of the heavy earnest of 85% washing with alcohol, merging filtrate is recycled to does not have the alcohol flavor, and it is an amount of to add Mel, adds to inject water to 10000 milliliter, and the adjustment pH value is 4.0-5.0, is loaded on after the check in the bottle, sterilizes, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99114946A CN1084205C (en) | 1999-06-17 | 1999-06-17 | Medicine for treating disease of upper respiratory tract and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99114946A CN1084205C (en) | 1999-06-17 | 1999-06-17 | Medicine for treating disease of upper respiratory tract and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1278443A CN1278443A (en) | 2001-01-03 |
| CN1084205C true CN1084205C (en) | 2002-05-08 |
Family
ID=5277975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN99114946A Expired - Fee Related CN1084205C (en) | 1999-06-17 | 1999-06-17 | Medicine for treating disease of upper respiratory tract and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1084205C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102058695B (en) * | 2011-01-11 | 2012-05-02 | 上海中医药大学 | Traditional Chinese medicine composition and preparation method and application thereof |
| CN102908444A (en) * | 2012-10-30 | 2013-02-06 | 杨晨 | Miao drug for treating lung disease |
| CN103656143A (en) * | 2013-12-16 | 2014-03-26 | 青岛百瑞吉生物工程有限公司 | Chinese herbal preparation for treating acute tonsillitis and preparation method thereof |
| CN112494573A (en) * | 2020-11-05 | 2021-03-16 | 云南金碧制药有限公司 | Sugar-free pharynx-soothing mixture and preparation method thereof |
| CN115463183B (en) * | 2022-09-17 | 2023-04-07 | 云南金碧制药有限公司 | Application of Yanshu mixture in preparation of medicine for treating new coronavirus |
| CN116159100B (en) * | 2022-09-17 | 2023-09-15 | 云南金碧制药有限公司 | Application of Yanshu mixture in preparing medicine for treating upper respiratory tract virus infection |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1103589A (en) * | 1993-12-09 | 1995-06-14 | 卜荣安 | Plaster for treating respiratory system diseases |
| CN1124634A (en) * | 1994-12-15 | 1996-06-19 | 广东省台山市台城制药厂 | Antitussive Chinese drug and preparing process thereof |
-
1999
- 1999-06-17 CN CN99114946A patent/CN1084205C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1103589A (en) * | 1993-12-09 | 1995-06-14 | 卜荣安 | Plaster for treating respiratory system diseases |
| CN1124634A (en) * | 1994-12-15 | 1996-06-19 | 广东省台山市台城制药厂 | Antitussive Chinese drug and preparing process thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1278443A (en) | 2001-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1084205C (en) | Medicine for treating disease of upper respiratory tract and its preparation | |
| CN1294015A (en) | Medicine for treating thyroid enlargement and thyroidism | |
| JPH08198768A (en) | Diabetes-treating agent | |
| CN1151823C (en) | Medicine for preventing and treating cold and its preparing process | |
| CN1081464C (en) | Chinese medicine for acute and chronic diarrhea, dysentery with purulent and bloody stools, as well as acute and chronic colitis | |
| CN1061264C (en) | Pure Chinese medicine for stopping drugs and its prepn. tech. | |
| CN1261151C (en) | Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method | |
| CN1589853A (en) | Compound preparation for treating mucosa ulceration | |
| CN1236810C (en) | Gastritis treating Chinese medicine | |
| CN1233408C (en) | Tablet medicine for treating pharyngolaryngitis and its preparation method | |
| CN100402073C (en) | Medicine for treating disease caused by heat toxin | |
| CN1197615C (en) | Antineoplastic medicine and its preparation process | |
| CN1470271A (en) | Chinese medicinal compound preparation for treating liver fibrillation disease and its preparation method | |
| CN1931242A (en) | Chinese medicine composition for treating cardio palmus and its prepn process | |
| CN100384457C (en) | New uses of vine | |
| CN1314409C (en) | Medicine for inhibiting and eliminating cancer | |
| CN1061252C (en) | Preparation of Chinese medicine for curing cardiac and cerebral diseases atomized by oxygen and its preparation process | |
| CN1041992C (en) | Preparation technology of cold resistant panacla tablet | |
| CN1058885C (en) | Drug-stopping addiction-removing capsule | |
| CN1292763C (en) | Chinese traditional medicine buccal tablets for preventing and treating caries and its preparation | |
| CN113134063A (en) | Traditional Chinese medicine composition for treating aphtha | |
| CN1113148A (en) | powdered medicine for treatment of laryngopathy and its preparation method | |
| CN1448167A (en) | Medicine for treatment of pelvic inflammation, its preparation and preparing method | |
| CN1079241C (en) | Chinese patent drug for curing cough and asthma | |
| CN102552774A (en) | Traditional Chinese medicine composition used for treating cough |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: YUNNAN PROV JINBI PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME OR ADDRESS: JINBI PHARMACEUTICAL FACTORY, YUNNAN |
|
| CP01 | Change in the name or title of a patent holder |
Patentee after: Yunnan Jinbi Pharmaceutical Co., Ltd. Patentee before: Yunnan Jinbi Pharmaceutical Factory |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20020508 Termination date: 20180617 |